In this video Dan Hedges walks through the Lockheed Martin (LM) Cyber World exhibit at the USA Science & Engineering festival. He is accompanied by LM’s Senior Strategist, Roya Mohadjer.

So how’s the festival been treating you so far?

“It’s been outstanding! We’ve had tons of parents, teachers and students. It’s been wonderful, thank you.”

Tell me a little bit about biometric facial recognition.

“So biometric facial recognition is very cool à It takes what we as humans can do naturally, recognizing people’s faces, and mimic that through the technology to be able to pick up faces in the crowds. Whether it be at the store, at a stadium, and anywhere that we find the need.”

What are some other technical challenges that the developers face implementing this software?

“So technical challenges, you know, it really has to do with how we detect the face. And since we’ve picked so many points across the face, whether it be the eyes, the cheeks, the chin, or the forehead, we’ve been able to mitigate any of that and accurately recognize your face.”

“So if you walk back by the booth now à it would pick up your face and memorize it for the day. [It is] able to know that you're not a [new] individual. You're actually a repeat person coming through. So it doesn’t count you separately.”

(Roya and Dan move towards the genomic medicine table)

Okay, tell me a little bit about genomic medicine.
“So at Lockheed Martin we’re identifying ways to decode the human genome sequence to be able to deliver personalized healthcare and medicine.”

What are some of the applications of genomic medicine?
“So think about it this way, right now maybe you go to the grocery store and you buy yourself Aleve or Motrin. It's really hard for you to figure out why a certain medicine isn't working with you. With the decoded genome sequence you can figure out everything that's going on in your system and be able to have personal branded medicine that can treat your issues directly. It’s more efficient.”

What's the status of the project now? How far are we from a full genomic solution to medical problems?
“Right now we're in research and development and we’re ready to deliver. But we’re working with our customers to figure out what the specific applications are.”